Compound research
Tirzepatide: Research Overview & Current Status
Tirzepatide is a GIP/GLP-1 dual receptor agonist. Current research status: fda-approved. Tirzepatide is FDA-approved under two brand names: Mounjaro (type 2 diabetes, approved May 2022) and Zepbound (chronic weight management, approved November 2023; obstructive sleep apnea indication added December 2024). Compounded (non-brand) tirzepatide is not FDA-approved and has been the subject of FDA enforcement actions.
Overview
Tirzepatide is a synthetic peptide developed by Eli Lilly that acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. It was the first dual incretin agonist to receive FDA approval, initially for type 2 diabetes (Mounjaro) and subsequently for chronic weight management (Zepbound).
GIP/GLP-1 dual receptor agonist
Research timeline
2022
FDA approved Mounjaro (tirzepatide) for type 2 diabetes, the first dual incretin (GIP/GLP-1) agonist approved, based on the SURPASS Phase 3 program (SURPASS-1 through 5, >10,000 participants).
Source →2022
SURPASS-2 head-to-head trial published in the New England Journal of Medicine reported superior A1C reduction versus semaglutide 1 mg.
Source →2023
FDA approved Zepbound (tirzepatide) for chronic weight management based on SURMOUNT-1 and SURMOUNT-2 Phase 3 trials; SURMOUNT-1 (N=2,539) reported up to 22.5% mean body weight reduction at 72 weeks at the 15 mg dose versus 2.4% placebo.
Source →2024
Zepbound received an additional FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity, based on the SURMOUNT-OSA trial.
Source →2025
SURMOUNT-5 head-to-head trial published in NEJM reported tirzepatide 15 mg produced approximately 20.2% weight loss versus 13.7% for semaglutide 2.4 mg over 72 weeks.
Source →
Active & recent research
SYNERGY-NASH
liver histology outcomes in metabolic dysfunction-associated steatohepatitis (MASH)
SURMOUNT-MMO
morbidity and mortality outcomes in adults with obesity, analogous to the SELECT trial design used for semaglutide
Key findings
- SURMOUNT-1 (N=2,539) reported mean body weight reductions of 15.0% (5 mg), 19.5% (10 mg), and 20.9-22.5% (15 mg) at 72 weeks versus approximately 3.1% with placebo.
- SURPASS-2 reported superior A1C reduction for tirzepatide versus semaglutide 1 mg in a head-to-head trial in adults with type 2 diabetes.
- SURMOUNT-5, the only head-to-head obesity trial versus semaglutide, reported tirzepatide 15 mg produced approximately 20.2% weight loss versus 13.7% for semaglutide 2.4 mg at 72 weeks.
- SURPASS trial program A1C reductions ranged from 1.87% to 2.58% depending on dose across more than 10,000 participants in five Phase 3 trials.
Safety & regulatory notes
Brand-name tirzepatide (Mounjaro, Zepbound) is FDA-approved with an established safety label. The FDA has separately flagged compounded (non-brand) tirzepatide as an unapproved product: as of July 2025 the agency had logged over 320 adverse event reports tied to compounded tirzepatide (part of over 1,150 combined with compounded semaglutide), largely linked to dosing errors, and in 2025 proposed excluding tirzepatide from the substances 503A/503B compounding pharmacies may legally use. FAERS-based academic analyses in 2025 have also examined comparative renal and other adverse-event signals between tirzepatide and semaglutide.
We may earn a commission when readers buy through links on this page, at no extra cost to you. Commissions never affect a vendor's score — every vendor is graded on the same public rubric built from published lab documentation, live catalog pricing, and community sentiment. How we score →
Where it's sold for research
We track vendor availability and published pricing for Tirzepatide on a dedicated page. See where to buy Tirzepatide →
Tirzepatide FAQ
Is tirzepatide FDA-approved?+
Yes, under two brand names: Mounjaro for type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity.
What is tirzepatide studied for?+
Approved and ongoing research covers type 2 diabetes glycemic control, chronic weight management, obstructive sleep apnea, cardiovascular outcomes, and MASH (fatty liver disease).
Is compounded tirzepatide legal and safe?+
The FDA has documented adverse events tied to compounded tirzepatide, largely linked to dosing errors and product quality issues, and moved in 2025 to restrict compounding of tirzepatide by outsourcing facilities; compounded versions are not FDA-approved.
How is tirzepatide different from semaglutide?+
Tirzepatide is a dual GIP/GLP-1 receptor agonist, while semaglutide acts on the GLP-1 receptor alone; a 2025 head-to-head trial (SURMOUNT-5) reported greater average weight loss with tirzepatide than semaglutide over 72 weeks.
Sources for this page (5)
- 1 https://www.biospace.com/article/fda-approves-lilly-s-zepbound-for-chronic-weight-management
- 2 https://healthrx.com/regulatory-mounjaro/global-regulatory
- 3 https://www.kalios.health/compounds/tirzepatide.html
- 4 https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-showed-superior-weight-loss-over-wegovy
- 5 https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Related: all compound research overviews · research radar · full vendor rankings · methodology